Novartis and Medicines for Malaria Venture (MMV) will progress ganaplacide/lumefantrine-solid dispersion formulation (SDF) into Phase III development for the treatment of patients with malaria due to Plasmodium falciparum. Ganaplacide is a novel agent with a new mechanism of action, which is combined with a new formulation of lumefantrine optimised for once-daily dosing. The combination has […]
